

CAR T-Cell Translation: The State of the Art (Recording)

Stanford University School of Medicine

References

1. Baggot, C., Kunicki, M., Pacenta, H. L., Rossoff, J., Talano, J. A., Chao, K., Verneris, M. R., Karras, N., Qayed, M., Krupski, C., Keating, A. K., Rabik, C. A., Chinnabhandar, V., Mackall, C. L., Curran, K. J., Schultz, L. M., Prabhu, S., Phillips, C. L., Stefanski, H. E., Moskop, A., Margossian, S., Myers, D., Brown, P. A., Hermiston, M., Satwani, P., Wilcox, R., Fabrizio, V. A., Goksenin, Y., Bhatia, S., & Laetsch, T. W. (2021). LBA7- Inferior Outcomes Among Black Patients with Childhood Acute Lymphoblastic Leukemia Following Tisagenlecleucel. *American Society for Transplantation and Cellular Therapy (ASTCT)*. <https://tct.confex.com/tct/2021/meetingapp.cgi/Paper/18094>
2. Barsan, V., Li, Y., Prabhu, S., Baggott, C., Nguyen, K., Pacenta, H., Phillips, C. L., Rossoff, J., Stefanski, H., Talano, J. A., Moskop, A., Baumeister, S., Verneris, M. R., Myers, G. D., Karras, N. A., Cooper, S., Qayed, M., Hermiston, M., Satwani, P., Krupski, C., ... Schultz, L. M. (2023). Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. *EClinicalMedicine*, 65, 102268. <https://doi.org/10.1016/j.eclinm.2023.102268>
3. Dekker, L., Calkoen, F. G., Jiang, Y., Blok, H., Veldkamp, S. R., De Koning, C., Spoon, M., Admiraal, R., Hoogerbrugge, P., Vormoor, B., Vormoor, H. J., Visscher, H., Bierings, M., Van Der Vlugt, M., Van Tinteren, H., Nijstad, A. L., Huitema, A. D. R., Van Der Elst, K. C. M., Pieters, R., Lindemans, C. A., ... Nierkens, S. (2022). Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. *Blood advances*, 6(7), 1969–1976. <https://doi.org/10.1182/bloodadvances.2021006700>
4. Eylon, M., Prabhu, S., John, S., King, M. J. M., Bhatt, D., Curran, K. J., Erickson, C., Karras, N. A., Phillips, C. L., Satwani, P., Hermiston, M., Southworth, E., Baumeister, S. H. C., Talano, J. A., MacMillan, M. L., Rossoff, J., Bonifant, C. L., Myers, G. D., Rouce, R. H., Toner, K., ... Schultz, L. M. (2023). Mediport use as an acceptable standard for CAR T cell infusion. *Frontiers in immunology*, 14, 1239132. <https://doi.org/10.3389/fimmu.2023.1239132>
5. Fabrizio, V. A., Boelens, J. J., Mauguen, A., Baggott, C., Prabhu, S., Egeler, E., Mavroukakis, S., Pacenta, H., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J. A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., ... Curran, K. J. (2022). Optimal fludarabine lymphodepletion

is associated with improved outcomes after CAR T-cell therapy. *Blood advances*, 6(7), 1961–1968. <https://doi.org/10.1182/bloodadvances.2021006418>

6. Harary, M., Dolmans, R. G. F., & Gormley, W. B. (2018). Intracranial Pressure Monitoring-Review and Avenues for Development. *Sensors (Basel, Switzerland)*, 18(2), 465. <https://doi.org/10.3390/s18020465>
7. Kaczanowska, S., Murty, T., Alimadadi, A., Contreras, C. F., Duault, C., Subrahmanyam, P. B., Reynolds, W., Gutierrez, N. A., Baskar, R., Wu, C. J., Michor, F., Altreuter, J., Liu, Y., Jhaveri, A., Duong, V., Anbunathan, H., Ong, C., Zhang, H., Moravec, R., Yu, J., ... Kaplan, R. N. (2024). Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. *Cancer cell*, 42(1), 35–51.e8. <https://doi.org/10.1016/j.ccell.2023.11.011>
8. Laetsch, T. W., Maude, S. L., Rives, S., Hiramatsu, H., Bittencourt, H., Bader, P., Baruchel, A., Boyer, M., De Moerloose, B., Qayed, M., Buechner, J., Pulsipher, M. A., Myers, G. D., Stefanski, H. E., Martin, P. L., Nemecek, E., Peters, C., Yanik, G., Khaw, S. L., Davis, K. L., ... Grupp, S. A. (2023). Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 41(9), 1664–1669. <https://doi.org/10.1200/JCO.22.00642>
9. Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., & Mackall, C. L. (2016). Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. *Cancer immunology research*, 4(10), 869–880. <https://doi.org/10.1158/2326-6066.CIR-15-0230>
10. Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., Nagaraja, S., Granja, J., de Bourcy, C. F. A., Majzner, R., Satpathy, A. T., Quake, S. R., Monje, M., Chang, H. Y., & Mackall, C. L. (2019). c-Jun overexpression in CAR T cells induces exhaustion resistance. *Nature*, 576(7786), 293–300. <https://doi.org/10.1038/s41586-019-1805-z>
11. Mahdi, J., Dietrich, J., Straathof, K., Roddie, C., Scott, B. J., Davidson, T. B., Prolo, L. M., Batchelor, T. T., Campen, C. J., Davis, K. L., Gust, J., Lim, M., Majzner, R. G., Park, J. R., Partap, S., Ramakrishna, S., Richards, R., Schultz, L., Vitanza, N. A., Wang, L. D., ... Monje, M. (2023). Tumor inflammation-associated neurotoxicity. *Nature medicine*, 29(4), 803–810. <https://doi.org/10.1038/s41591-023-02276-w>
12. Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., Geraghty, A. C., Good, Z., Mochizuki, A. Y., Gillespie, S. M., Toland, A. M. S., Mahdi, J., Reschke, A., Nie, E. H., Chau, I. J., Rotiroti, M. C., ... Monje, M. (2022). GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. *Nature*, 603(7903), 934–941. <https://doi.org/10.1038/s41586-022-04489-4>

13. Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., Baruchel, A., ... Grupp, S. A. (2018). Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *The New England journal of medicine*, 378(5), 439–448.
<https://doi.org/10.1056/NEJMoa1709866>
14. Mcnerney, K. O., Fabrizio, V. A., Talleur, A. C., Si Lim, S., Dreyzin, A., Baggott, C., Vatsayan, A., Prabhu, S., Rossoff, J., Pacent, H. L., Phillips, C. L., Talano, J. A., Moskop, A., Verneris, M. R., Myers, D., Karras, N., Bonifant, C. L., Qayed, M., Hermiston, M., Satwani, P., Krupski, C., Keating, A. K., Baumeister, S. H. C., Chinnabhandar, V., Egeler, E., Mavroukakis, S., Curran, K. J., Mackall, C. L., Laetsch, T. W., Schultz, L. M., & Naik, S. (2024). Risk Factors for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia. *Transplantation and Cellular Therapy*, 30(2), pp. S219-S220.
<https://doi.org/10.1016/j.jtct.2023.12.285>
15. Moskop, A., Pommert, L., Baggott, C., Prabhu, S., Pacent, H. L., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J. A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M. L., Satwani, P., Krupski, C., Keating, A. K., Wilcox, R., ... Schultz, L. M. (2022). Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. *Blood advances*, 6(14), 4251–4255.
<https://doi.org/10.1182/bloodadvances.2021006393>
16. Mount, C. W., Majzner, R. G., Sundaresh, S., Arnold, E. P., Kadapakkam, M., Haile, S., Labanieh, L., Hulleman, E., Woo, P. J., Rietberg, S. P., Vogel, H., Monje, M., & Mackall, C. L. (2018). Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. *Nature medicine*, 24(5), 572–579. <https://doi.org/10.1038/s41591-018-0006-x>
17. Myers, R. M., Li, Y., Barz Leahy, A., Barrett, D. M., Teachey, D. T., Callahan, C., Fasano, C. C., Rheingold, S. R., DiNofia, A., Wray, L., Aplenc, R., Baniewicz, D., Liu, H., Shaw, P. A., Pequignot, E., Getz, K. D., Brogdon, J. L., Fesnak, A. D., Siegel, D. L., Davis, M. M., ... Maude, S. L. (2021). Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 39(27), 3044–3055.
<https://doi.org/10.1200/JCO.20.03458>
18. Quintarelli, C., Camera, A., Ciccone, R., Alessi, I., Del Bufalo, F., Carai, A., Del Baldo, G., Mastronuzzi, A., & De Angelis, B. (2021). Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?. *Frontiers in immunology*, 12, 634031. <https://doi.org/10.3389/fimmu.2021.634031>
19. Ramakrishna, S., Kaxzanowska, S., Murty, T., Contreras, C. F., Merchant, M., Glod, J., Gutierrez, N., Alimadadi, A., Stroncek, D., Highfill, S., Duault, C., Subrahmanyam, P. B.,

- Holmes, T., Reynolds, W., Baskar, R., Barge, A., Lyon, H., Moravec, R., Ranasinghe, S., Yu, J., Biswas, R., Pollack, S., Van Nostrand, S., Lindsay, J., Pichavant, M., Sahaf, B., Bendall, S. C., Gentles, A. J., Maecker, H., Hedrick, C. C., Mackall, C., & Kaplan, R. (2022). Abstract CT142: GD2.Ox40.CD28.z CAR T cell trial in neuroblastoma and osteosarcoma. *Cancer Research*, 82(12) CT142. <https://doi.org/10.1158/1538-7445.AM2022-CT142>
20. Ravich, J. W., Huang, S., Zhou, Y., Brown, P., Pui, C. H., Inaba, H., Cheng, C., Gottschalk, S., Triplett, B. M., Bonifant, C. L., & Talleur, A. C. (2022). Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel. *Transplantation and cellular therapy*, 28(2), 73.e1–73.e9. <https://doi.org/10.1016/j.jtct.2021.11.019>
21. Rives, S., Maude, S. L., Hiramatsu, H., Baruchel, A., Bader, P., Bittencourt, H., Buechner, J., Laetsch, T., De Moerloose, B., Qayad, M., Stefanski, H. E., Davis, K. L., Martin, P. L., Nemecek, E., Peters, C., Yanik, G., Balduzzi, A., Boissel, N., Khaw, S. L., Krueger, J., Levine, J., Davies, S., Meyers, G. D., Yeo, A., O'Donovan, D., Ramos, R., Pulsipher, M., & Grupp, S. (2022). S112: Tisagenlecleucel In Pediatric And Young Adult Patients (PTS) With Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-All): Final Analyses From The Eliana Study. *HemaSphere*, 6, pp. 13-14. <https://doi.org/10.1097/01.HS9.0000843344.19780.98>
22. Rossoff, J., Baggott, C., Prabhu, S., Pacent, H., Phillips, C. L., Stefanski, H., Talano, J. A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N., Brown, P. A., Qayed, M., Hermiston, M., Satwani, P., Krupski, C., Keating, A. K., Wilcox, R., Rabik, C. A., ... Schultz, L. M. (2021). Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. *Blood*, 138(21), 2138–2142. <https://doi.org/10.1182/blood.2021012392>
23. Schultz, L. M., Baggott, C., Prabhu, S., Pacent, H. L., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J. A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., Satwani, P., Krupski, C., Keating, A. K., Wilcox, R., ... Laetsch, T. W. (2022). Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 40(9), 945–955. <https://doi.org/10.1200/JCO.20.03585>
24. Stefanski, H. E., Eaton, A., Baggott, C., Rossoff, J., Verneris, M. R., Prabhu, S., Pacent, H. L., Phillips, C. L., Talano, J. A., Moskop, A., Margossian, S. P., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., Satwani, P., Krupski, M. C., Keating, A. K., Wilcox, R., ... Schultz, L. M. (2023). Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. *Blood advances*, 7(4), 541–548. <https://doi.org/10.1182/bloodadvances.2022007246>

25. Vandris, P., Chao, K., Baggott, C., Phillips, C. L., Qayed, M., Rossoff, J., Si Lim, S. J., Winestone, L. E., Stefanski, H. E., Talano, J. A., Margossian, S., Verneris, M. R., Meyers, G. D., Karras, N. A., Brown, P. A., Satwani, P., Mackall, C., Curran, K. J., Laetsch, T. W., & Schultz, L. M. (2022). Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel. *Journal of Clinical Oncology*, *40*(16).
https://doi.org/10.1200/JCO.2022.40.16_suppl.10016